Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label bimekizumab study in adults with psoriasis
jRCT2080224002Phase 3Completed
- Sponsor
- UCB
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of bimekizumab in plaque psoriasis, generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) (2 cohorts), sponsored by UCB. Primary endpoints: Long-term safety, Long-term tolerability and 1 more. Started Aug 2018; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasisgeneralized pustular psoriasis (GPP)erythrodermic psoriasis (EP)
Beyond the preview
Go deeper on jRCT2080224002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224002.